Beta-Blockers in Pregnancy: Clinical Update

[1]  L. Dugoff,et al.  Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension During Pregnancy , 2022, Obstetric Anesthesia Digest.

[2]  A. Khashan,et al.  Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records , 2022, Hypertension.

[3]  G. Mancia,et al.  Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. , 2022, Hypertension.

[4]  N. Zakiyah,et al.  Antihypertensive Medications for Severe Hypertension in Pregnancy: A Systematic Review and Meta-Analysis , 2022, Healthcare.

[5]  J. Singer,et al.  Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses , 2022, Hypertension.

[6]  Dhanunjaya R. Lakkireddy,et al.  Arrhythmias in Pregnancy. , 2021, JACC. Clinical electrophysiology.

[7]  S. V. van Kuijk,et al.  Blood pressure adjustments throughout healthy and hypertensive pregnancy: A systematic review and meta-analysis. , 2021, Pregnancy hypertension.

[8]  Muluneh M. Fashe,et al.  The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions , 2021, Expert opinion on drug metabolism & toxicology.

[9]  N. Hannan,et al.  Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia , 2021, Journal of clinical medicine.

[10]  S. V. van Kuijk,et al.  Adaptation of left ventricular diastolic function to pregnancy: a systematic review and meta-analysis , 2021, Journal of hypertension.

[11]  A. Khashan,et al.  Impact of Chronic Hypertension and Antihypertensive Treatment on Adverse Perinatal Outcomes: Systematic Review and Meta‐Analysis , 2021, Journal of the American Heart Association.

[12]  V. Schiffer,et al.  Preventing Recurrent Preeclampsia by Tailored Treatment of Nonphysiologic Hemodynamic Adjustments to Pregnancy , 2021, Hypertension.

[13]  Qi Chen,et al.  Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia , 2021, Journal of Human Hypertension.

[14]  A. Morton.  Physiological Changes and Cardiovascular Investigations in Pregnancy. , 2020, Heart, lung & circulation.

[15]  S. Oparil,et al.  Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[16]  Yin Wu,et al.  Risk of congenital malformations in offspring of women using β‐blockers during early pregnancy: An updated meta‐analysis of observational studies , 2020, British journal of clinical pharmacology.

[17]  N. Wenger,et al.  Hypertension During Pregnancy , 2020, Current Hypertension Reports.

[18]  H. Kay,et al.  Labetalol-Induced Hepatotoxicity during Pregnancy: A Case Report , 2020, American Journal of Perinatology Reports.

[19]  L. Magee,et al.  Toward personalized management of chronic hypertension in pregnancy , 2020, American Journal of Obstetrics and Gynecology.

[20]  V. Pergialiotis,et al.  Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network meta-analysis. , 2020, American journal of obstetrics and gynecology.

[21]  M. Hoeltzenbein,et al.  Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. , 2020, Journal of hypertension.

[22]  Lorie M. Harper,et al.  Chronic Hypertension in Pregnancy. , 2019, American journal of obstetrics and gynecology.

[23]  M. Walker,et al.  First-line antihypertensive treatment for severe hypertension in pregnancy: A systematic review and network meta-analysis. , 2019, Pregnancy hypertension.

[24]  J. Pell,et al.  In Utero Antihypertensive Medication Exposure and Neonatal Outcomes , 2019, Hypertension.

[25]  M. Walker,et al.  First-line antihypertensive treatment for severe hypertension in pregnancy: A systematic review and network meta-analysis. , 2019, Pregnancy hypertension.

[26]  Amy E. Judy,et al.  ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease. , 2019, Obstetrics and gynecology.

[27]  A. Brateanu,et al.  Hypertension in pregnancy: Pathophysiology and treatment , 2019, SAGE open medicine.

[28]  S. Karumanchi,et al.  Preeclampsia: Pathophysiology, Challenges, and Perspectives , 2019 .

[29]  ACOG Practice Bulletin No. 29: Chronic Hypertension in Pregnancy , 2001, Obstetrics and gynecology.

[30]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[31]  S. Hernández-Díaz,et al.  -Blocker Use in Pregnancy and the Risk for Congenital Malformations , 2018, Annals of Internal Medicine.

[32]  M. Hoeltzenbein,et al.  Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study , 2018, Journal of hypertension.

[33]  Wansu Chen,et al.  Beta‐blocker subtypes and risk of low birth weight in newborns , 2018, Journal of clinical hypertension.

[34]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[35]  M. Browne,et al.  Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997–2011 , 2018, Maternal and Child Health Journal.

[36]  M. Loane,et al.  Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study , 2017, Drug Safety.

[37]  J. Pell,et al.  In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review , 2017, Journal of hypertension.

[38]  Wansu Chen,et al.  &bgr;-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies , 2017, JAMA internal medicine.

[39]  P. Seed,et al.  Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[40]  T. Tomimatsu,et al.  Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction , 2017, Hypertension Research.

[41]  S. V. van Kuijk,et al.  Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta‐analysis , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[42]  R. Touyz,et al.  Oxidative Stress, Inflammation, and Vascular Aging in Hypertension , 2017, Hypertension.

[43]  T. Ikeda,et al.  Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[44]  S. Hernández-Díaz,et al.  Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia , 2016, Pediatrics.

[45]  Belinda Jim,et al.  Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[46]  J. Singer,et al.  Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial , 2016, BJOG : an international journal of obstetrics and gynaecology.

[47]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[48]  C. Julian,et al.  Regulation of Sympathetic Nerve Activity During the Cold Pressor Test in Normotensive Pregnant and Nonpregnant Women , 2015, Hypertension.

[49]  M. Werler,et al.  Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case–control study , 2015, BJOG : an international journal of obstetrics and gynaecology.

[50]  G. Koren,et al.  Labetalol for hypertension in pregnancy , 2015, Expert opinion on drug safety.

[51]  D. Krewski,et al.  Beta‐Blockers increase the risk of being born small for gestational age or of being institutionalised during infancy , 2014, BJOG: an International Journal of Obstetrics and Gynaecology.

[52]  S. Hernández-Díaz,et al.  The Risk of Congenital Malformations Associated With Exposure to &bgr;-Blockers Early in Pregnancy: A Meta-Analysis , 2013, Hypertension.

[53]  L. Køber,et al.  β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study , 2012, BMJ Open.

[54]  Mike Kirby,et al.  ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy , 2012 .

[55]  R. Cavalli,et al.  Determination of pindolol enantiomers in amniotic fluid and breast milk by high-performance liquid chromatography: applications to pharmacokinetics in pregnant and lactating women. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[56]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[57]  K. Javorka,et al.  [The autonomic nervous system and hypertension]. , 2001, Ceskoslovenska fysiologie.

[58]  L D Edmonds,et al.  The National Birth Defects Prevention Study , 2001, Public health reports.